Literature DB >> 32130072

The role of the sphingolipid pathway in liver fibrosis: an emerging new potential target for novel therapies.

Yuval Ishay1, Dean Nachman1, Tawfik Khoury2, Yaron Ilan2.   

Abstract

Sphingolipids (SL) are a family of bioactive lipids and a major cellular membrane structural component. SLs include three main compounds: ceramide (Cer), sphingosine (Sp), and sphingosine-1-phosphate (S-1P), all of which have emerging roles in biological functions in cells, especially in the liver. They are under investigation in various liver diseases, including cirrhosis and end-stage liver disease. In this review, we provide an overview on the role of SLs in liver pathobiology and focus on their potential role in the development of hepatic fibrosis. We describe recent evidence and suggest SLs are a promising potential therapeutic target for the treatment of liver disease and fibrosis.

Entities:  

Keywords:  inflammation; liver fibrosis; sphingolipids; sphingosine kinase

Year:  2020        PMID: 32130072     DOI: 10.1152/ajpcell.00003.2020

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  6 in total

1.  Sphingosine kinase 1 mediates sexual dimorphism in fibrosis in a mouse model of NASH.

Authors:  David Montefusco; Maryam Jamil; Melissa A Maczis; William Schroeder; Moshe Levi; Suman Ranjit; Jeremy Allegood; Dipankar Bandyopadhyay; Reuben Retnam; Sarah Spiegel; L Ashley Cowart
Journal:  Mol Metab       Date:  2022-06-06       Impact factor: 8.568

2.  The role of the sphingosine axis in immune regulation: A dichotomy in the anti-inflammatory effects between sphingosine kinase 1 and sphingosine kinase 2-dependent pathways.

Authors:  Yuval Ishay; Dvorah Rotnemer-Golinkin; Yaron Ilan
Journal:  Int J Immunopathol Pharmacol       Date:  2021 Jan-Dec       Impact factor: 3.219

Review 3.  Fat and Protein Combat Triggers Immunological Weapons of Innate and Adaptive Immune Systems to Launch Neuroinflammation in Parkinson's Disease.

Authors:  Shelby Loraine Hatton; Manoj Kumar Pandey
Journal:  Int J Mol Sci       Date:  2022-01-19       Impact factor: 5.923

4.  Augmented antiviral T cell immunity by oral administration of IMM-124E in preclinical models and a phase I/IIa clinical trial: A method for the prevention and treatment of COVID-19.

Authors:  Yuval Ishay; Assaf Potruch; Sarah Weksler-Zangen; Yehudit Shabat; Yaron Ilan
Journal:  Drug Dev Res       Date:  2021-10-01       Impact factor: 5.004

5.  Quantitative modeling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease.

Authors:  Partho Sen; Olivier Govaere; Tim Sinioja; Aidan McGlinchey; Dawei Geng; Vlad Ratziu; Elisabetta Bugianesi; Jörn M Schattenberg; Antonio Vidal-Puig; Michael Allison; Simon Cockell; Ann K Daly; Tuulia Hyötyläinen; Quentin M Anstee; Matej Orešič
Journal:  iScience       Date:  2022-08-15

6.  Toxicant-Induced Metabolic Alterations in Lipid and Amino Acid Pathways Are Predictive of Acute Liver Toxicity in Rats.

Authors:  Venkat R Pannala; Shanea K Estes; Mohsin Rahim; Irina Trenary; Tracy P O'Brien; Chiyo Shiota; Richard L Printz; Jaques Reifman; Masakazu Shiota; Jamey D Young; Anders Wallqvist
Journal:  Int J Mol Sci       Date:  2020-11-04       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.